ArticleOncoTargets and therapy2016
Association of polymorphisms in interleukin-8 gene with cancer risk: a meta-analysis of 22 case-control studies.
Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cumulative Evidence for Association Between IL-8 -251T>A and IL-18 -607C>A Polymorphisms and Colorectal Cancer Susceptibility: a Systematic Review and Meta-analysis.Journal of gastrointestinal cancer · 2021Pooled it
- Association between interleukin-8 gene -251 A/T polymorphism and the risk of coronary artery disease: A meta-analysis.Medicine · 2019Pooled it
- A case-control study on IL-8 gene polymorphisms and serum IL-8 levels in patients with age-related macular degeneration in India.Human genetics · 2026Article
- Six IL-8 gene polymorphisms and the entire cancer susceptibility according to a comprehensive analysis especially in prostate cancer.Clinics (Sao Paulo, Brazil) · 2026Article
- IL-8 receptor signaling as a novel target for angiogenic retinopathies.Angiogenesis · 2025Article
- Associations between single nucleotide polymorphisms of cytokines and hepatitis B virus-related liver cirrhosis: A case-control study.Immunity, inflammation and disease · 2024Article
- IL-8 (CXCL8) Correlations with Psychoneuroimmunological Processes and Neuropsychiatric Conditions.Journal of personalized medicine · 2024Review
- Article
- Effect of novel IL-8 gene mutation on its protein structure and stability among ovarian cancer patients in Saudi Arabia.Bioinformation · 2024Article
- The Significant Impacts of Interleukin-8 Genotypes on the Risk of Colorectal Cancer in Taiwan.Cancers · 2023Article
- Evaluation of interleukin 8 polymorphisms (-251T/A and +781C/T) in patients with hepatocellular carcinoma: a meta-analysis.Clinical and experimental hepatology · 2021Article
- Relevance of Interleukins 6 and 8 Single Nucleotide Polymorphisms in Prostate Cancer: A Multicenter Study.Prostate cancer · 2021Article
- Interleukin-8 and nuclear factor kappa B are increased and positively correlated in myelodysplastic syndrome.Medical oncology (Northwood, London, England) · 2017Article
- IL-8 -251A/T and +781C/T polymorphisms were associated with risk of breast cancer in a Chinese population.International journal of clinical and experimental pathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-8 (IL-8) is a kind of chemokine that plays an important role in the development and progression of many human malignancies. Previous studies have uncovered that polymorphisms in IL-8 is associated with the risk of many cancer types, but the results were inconsistent and inconclusive. In the present study, we aimed to explore the roles of IL-8 polymorphisms (rs2227307, rs2227306, +678T/C, rs1126647, and +1633C/T) and cancer risk through a systematic review and meta-analysis. Potential source of heterogeneity was sought out through sensitivity analysis. Desirable data were extracted and registered into databases. Finally, a total of ten publications comprising of 22 case-control studies, including 4,259 cases and 7,006 controls were ultimately eligible for the meta-analysis. No significant association was uncovered for all the five polymorphisms and the overall cancer risk. However, in the stratification analysis by cancer type, a significantly decreased risk of hepatocellular carcinoma was identified for rs2227306 polymorphism (T vs C: odds ratio [OR] =0.721, 95% confidence interval [CI] =0.567-0.916, Pz =0.007; TT vs CC: OR =0.447, 95% CI =0.274-0.728, Pz =0.001; TT vs TC + CC: OR =0.480, 95% CI =0.304-0.760, Pz =0.002). In conclusion, our data shows that rs2227306 polymorphism plays a protective role in hepatocellular carcinoma risk. Future well-designed studies with a larger sample size are warranted to verify our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.